respiratory syncytial virus (RSV)-mediated lower respiratory tract disease

news

Pfizer maternal RSV vaccine approved

22 August 2023 | By Catherine Eckford (European Pharmaceutical Review)

The US Food and Drug Administration (FDA) has authorised an RSV vaccine for pregnant individuals, which in one study, reduced the risk of severe LRTD by 81.8 percent within 90 days after birth.

news

First RSV vaccine approved for older adults

4 May 2023 | By Catherine Eckford (European Pharmaceutical Review)

The US Food and Drug Administration (FDA) has approved the first-ever vaccine for respiratory syncytial virus (RSV) in adults over 60 years old.

news

mRNA vaccine trial shows efficiency in older adults with RSV

18 January 2023 | By Catherine Eckford (European Pharmaceutical Review)

Moderna's mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults demonstrated promising efficacy in a Phase III trial.

news

Could GSK offer the first RSV older adult vaccine?

3 November 2022 | By Catherine Eckford (European Pharmaceutical Review)

The EMA has accepted a marketing application for an RSV vaccine intended for older adults, the first potential vaccine for this age group with lower respiratory tract disease.

news

Janssen’s RSV vaccine provides 80 percent protection in Phase II study

4 October 2021 | By Anna Begley (European Pharmaceutical Review)

The investigational respiratory syncytial virus (RSV) vaccine candidate demonstrated 80 percent efficacy in adults aged 65 and older.

news

Respiratory virus vaccine receives breakthrough therapy designation

5 September 2019 | By Victoria Rees (European Pharmaceutical Review)

The FDA has awarded a breakthrough therapy designation to an investigational prophylactic vaccine to treat respiratory syncytial virus in seniors.